TriangleHEALTH PROFESSIONAL · SOURCE READING
Response to initial treatment
Source: Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 21, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Risk-Based Treatment Assignment / Prognostic Factors Affecting Risk-Based Treatment
The rapidity with which leukemia cells are eliminated after initiation of treatment and the level of residual disease at the end of induction are associated with long-term outcome. Because treatment response is influenced by the drug sensitivity of leukemic cells and host pharmacodynamics and pharmacogenomics,[129] early response has strong prognostic significance. Various ways of evaluating the leukemia cell response to treatment have been used, including the following:
Source links and citations
MRD determination in bone marrow at the end of induction (EOI) and end of consolidation (EOC).
Source links and citations
Day 7 and day 14 bone marrow responses.
Source links and citations
Peripheral blood response to steroid prophase.
Source links and citations
Peripheral blood response to multiagent induction therapy.
Source links and citations
Peripheral blood MRD before end of induction (day 8, day 15).
Source links and citations
Persistent leukemia at the end of induction (induction failure).
Source links and citations
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice